Clinical

Richard Adler, MD, FACS, provides insights on data presented at AA0 2023, from a study comparing results of the ARMOR procedure versus treatment with cyclosporine ophthalmic emulsion 0.05% in patients with dry eye disease.

Richard Adler, MD, FACS, discusses corneal fluorescein staining data presented at AAO 2023 from the pooled analysis of 2 phase 3 studies.

Richard Adler, MD, FACS, leads a discussion on real-world signs, symptoms and patient reactions associated with the treatment for DED.

Deborah Stephens, DO, shares unmet needs in the current treatment landscape of CLL and SLL.

A panel of experts explore current treatment strategies in CLL and SLL management.

Clinical manifestations and impact on patient quality of life amid diagnosis and management of CLL and SLL are discussed.

Richard Adler, MD, FACS, discusses the Switch trial which compared OTX-101 (cyclosporine ophthalmic solution 0.09%) vs cyclosporine ophthalmic emulsion 0.05% (Restasis) in patients with dry eye disease (DED).

The panel provides closing thoughts on the future of the CSCC and BCC treatment landscape.

Exploring recent trials and updates in nonmelanoma skin cancer treatment.

New methods of classifying patients could pave the way for more personalized treatment approaches, a new report states.

An analysis of the DELIVER trial also revealed an association between dapagliflozin treatment and reduced risk of cardiovascular death among individuals with heart failure with improved ejection fraction (HFimpEF).

Sarepta Therapeutics has started screening participants for a Phase 3 clinical trial to test its gene therapy candidate SRP-9003 in children with limb-girdle muscular dystrophy type 2E; wastewater testing points to a new COVID-19 infection wave fueled by the JN.1 variant; most patients on anti-obesity medications kept at least some weight off up to a year after they stopped taking them.

Global warming, wildfires, precipitation, floods, and storms impact patients with atopic dermatitis (AD).

A new report compared the blood immune repertoires of patients with chronic lymphocytic leukemia (CLL) who received chemoimmunotherapy and those who received ibrutinib.

The researchers explained that their findings expanded upon evidence of the harmful respiratory effects of night shifts while also providing valuable evidence for the development of COPD prevention strategies.

Compared with a hemoglobin A1c (HbA1c) level of 5.5%, adolescents with overweight or obesity were 72 times more likely to have diabetes if their HbA1c was 6.3% to 6.4%.

In a cohort with more than half a million women with endometrial, ovarian, or cervical cancer, less than 1% were enrolled in a clinical trial, and more than 85% of enrolled women were White.

A multidisciplinary approach is needed in patients with pulmonary arterial hypertension (PAH) who contract COVID-19, as they may experience worse outcomes.

A real-world study conducted across 9 European countries found that bolus injection frequency and engagement with a smart pen to administer insulin were associated with improved glycemic control among young adult patients with type 1 diabetes (T1D).

Key considerations for transitioning patients receiving bispecific therapy between care settings are highlighted.

The panelists discuss 24/7 bispecific care protocols for urgent healthcare needs.

People of color with scalp psoriasis experienced significant improvement in scalp itch and patient-reported health-related quality-of-life outcomes.

Virtual reality (VR) combined with pulmonary rehabilitation was more effective than pulmonary rehabilitation alone in improving the pulmonary function, exercise capacity, and mental health of patients with chronic obstructive pulmonary disease (COPD).

The study provides proof of principle for a novel approach to early detection of ovarian cancer based on an assessment of genomic instability patterns in DNA from Papanicolaou (Pap) smears.

Once treated with a one-size-fits-all approach, changes in the landscape for myasthenia gravis are allowing for more precise treatment of the disease.

Researchers found that venetoclax, either alone or post treatment with a Bruton tyrosine kinase inhibitor (BTKi), was safe and effective for patients with chronic lymphocytic leukemia (CLL).

Most patients in the cohort received rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for first-line therapy; hospitalization was prevalent; and average medical and pharmacy costs were more than $140,000 per patient per year.

An overview of the current landscape of available treatment options for Demodex blepharitis is analyzed.

Dr Metersky provides an overview of current treatment strategies for managing patients diagnosed with bronchiectasis.

The new Innovation in Behavioral Health (IBH) Model is designed to test for improving outcomes for adults with mental health and substance use disorder; patients with long COVID show prolonged activation of the immune system’s complement system after an acute infection; scientists now believe our bodies benefit most when our sleep is consistent, not just long.